Biotech Patent Practitioners to Gain Unique Insights at Upcoming Boston Conference

Nov. 11, 2011 - PRLog -- Biotech patent circles are buzzing over the opportunity to engage USPTO patent examiners in an exclusive session at the American Conference Institute’s 13th Advanced Forum on Biotech Patents later this month in Boston.  Called the Interactive Working Group Session: Integrating Changes at the PTO into Biotech Patent Practice, it will feature senior patent examiners and patent experts sharing their thoughts on the latest changes at the U.S. Patent and Trademark Office, including how the reforms wrought by the America Invents Act will impact patent prosecution.      
“For nearly a decade this conference has been an industry leader in disseminating the latest developments in biotech patent practice,” noted Stephanie Butler, a Division Manager at ACI.  “And attendees having the chance to address their concerns directly to patent examiners in an extended question-and-answer session like this is a rare opportunity.”  The three hour session, slated for the morning of November 30, 2011, kicks off a two day long conference that is expected feature discussions on:

-   The America Invents Act and how its reforms will change the patent code
-   The latest news on the promulgation of a biosimilars approval pathway by the FDA
-   Defense of inequitable conduct claims following the Therasense case
-   Analysis of the CAFA’s Myriad opinion and the next step in patentable subject matter debates
-   Experts’ views on the best practices for international patent filing

Butler was quick to point out the advantages of attending the post-conference session, The Master Class on Successful and Practical Strategies for Patenting Antibodies, as well.  “These are among the most critical biotech products out there, their IP must properly protect them, and this session will lay out the best ways to do that,” she said.  The 13th Advanced Forum on Biotech Patents will be held at the Omni Parker House Hotel in Boston from November 30 – December 1, 2011.  For more information visit www.americanconference.com/biotech-patents.